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Abstract
Regulation of MHC class I gene expression is critical to achieve proper immune surveillance. In this work, we identify
elements downstream of the MHC class I promoter that are necessary for appropriate in vivo regulation: a novel barrier
element that protects the MHC class I gene from silencing and elements within the first two introns that contribute to tissue
specific transcription. The barrier element is located in intergenic sequences 39 to the polyA addition site. It is necessary for
stable expression in vivo, but has no effect in transient transfection assays. Accordingly, in both transgenic mice and stably
transfected cell lines, truncation of the barrier resulted in transcriptional gene silencing, increased nucleosomal density and
decreased histone H3K9/K14 acetylation and H3K4 di-methylation across the gene. Significantly, distinct sequences within
the barrier element govern anti-silencing and chromatin modifications. Thus, this novel barrier element functions to
maintain transcriptionally permissive chromatin organization and prevent transcriptional silencing of the MHC class I gene,
ensuring it is poised to respond to immune signaling.
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Introduction
Major histocompatibility complex class I (MHC I) molecules
provide immune surveillance against intracellular pathogens [1].
MHC class I genes are ubiquitously expressed, but in a tissue-
specific manner [2]. Their expression is regulated primarily at the
transcriptional level and can be modulated both positively and
negatively by different stimuli [3–6]. Regulation of MHC class I
expression level is crucial for proper immune responses. Thus, over-
expression of MHC class I is correlated with induction of several
autoimmune diseases [7–12]. Conversely, MHC class I down-
regulation is associated in many cancers with disease progression,
therapy resistance and reduced survival [13–15]. Down-regulation
of MHC class I surface expression is also observed in cells infected
with HIV-1 [16,17] or transformed by oncogenic viruses [18,19],
oftenresultingfromepigenetic alterationsacrossMHCclass Igenes,
including histones deacetylation and DNA hypermethylation [19–
21]. Taken together, these observations emphasize the importance
of understanding the mechanisms that regulate MHC class I
expression and epigenetic integrity.
Wepreviouslyreportedthe generationoftransgenicmicecarrying
MHC class I gene, PD1. The PD1 transgene is a 9 Kb genomic
DNA fragment that contains 4 Kb of swine MHC class I coding
sequences, 1 Kb of sequences 59 to the transcription start site (TSS)
and 4 Kb downstream of the polyadenylation site. In mice, the PD1
transgene displays patterns of expression and cytokine responses that
parallel those of the endogenous classical MHC class I gene [22],
suggesting that 1) the short 9 Kb sequence contains the full
regulatory unit for proper expression of the MHC class I gene and
2) regulatory mechanisms are fully conserved across species [23].
Detailed in vivo and ex vivo molecular analyses of the promoter of
MHC class I gene have identified a series of regulatory DNA
sequence elements 59 to the coding sequences that serve to
establish proper patterns of gene expression [24,25]. Tissue-
specific expression is achieved through the combined effects of a
promoter-distal complex regulatory element located between -700
and –800 bp, and a series of promoter-distal elements [2,26,27].
Hormone/cytokine signaling is mediated through a series of
promoter-proximal elements, located between –68 and –500 bp
[3,5]. The cognate DNA-binding transcription factors that interact
with these promoter-proximal and -distal DNA sequence elements
have been identified [4,6]. At the core promoter, differences in Pol
II occupancy correlate with differences in rates of transcription (J.
Weissman and D. Singer, manuscript in preparation, 2009).
Despite the detailed understanding of the role of promoter DNA
sequence elements and transcription factors in establishing tissue-
specific levels of MHC class I expression and hormone/cytokine-
mediated responses, little is known about either the role of
downstream sequence elements or of chromatin structure in the
regulation of this gene family. Recently, we reported the surprising
finding that chromatin structure does not actively regulate
transcription of the class I gene: nucleosomal occupancy and
positioning are indistinguishable in tissues that differ in class I
expression levels by an order of magnitude and do not vary upon
either induction or inhibition of transcription. Rather, the
chromatin organization functions to keep the core promoter
poised and accessible for transcription, allowing rapid activation of
the gene without chromatin remodeling [28]. These findings are
consistent with the stable expression of the PD1 transgene and
suggested the possible existence of a barrier element within the
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chromatin structure.
In the present study, we have examined the role of sequences
downstream of the promoter in regulating MHC class I gene
expression. We demonstrate that the promoter alone is not
sufficient for proper regulation of PD1 expression in vivo. Rather,
stable PD1 expression and transcription-permissive chromatin
organization depend on the presence of a 39 barrier element
downstream of the PD1 gene. Distinct barrier element sequences
are necessary to prevent silencing and to maintain an open
chromatin organization across the MHC class I gene both in
transgenic mice and in stably transfected cells. In addition,
sequence elements within the introns contribute to the proper
regulation of tissue specific expression.
Results
Sequences downstream of the promoter of the MHC
class I gene, PD1, are required for proper in vivo
expression
To determine whether the PD1 promoter contains all the
regulatory elements necessary for normal in vivo expression,
transgenic mice were generated from a construct containing the
1 Kb PD1 promoter segment ligated to a human CD2 reporter
[29]. In contrast to the genomic PD1 transgenic lines, none of the
nine independent PD1-CD2 lines expressed the CD2 reporter
transgene (Figure 1A, top panel; Table 1). Similarly, when the
class I promoter was ligated to a GFP reporter, none of 6
independent transgenic lines generated from this construct
expressed GFP protein or RNA (J.Lovchick and D. Singer,
unpublished observations). Thus, although the extended 1 Kb
PD1 promoter is functional and regulated in transient transfection
assays [3,24], it is insufficient to direct stable class I transcription in
transgenic mice, suggesting that sequences downstream of the
transcription start site are necessary in vivo.
Intronic sequences regulate tissue-specific MHC class I
gene expression
To begin to map the minimal 39 sequence requirements for
stable MHC class I expression, we first truncated the 9 Kb
genomic fragment used to generate the PD1 transgenic mouse,
removing 3.7 Kb of distal intergenic sequences 39 to the PD1
gene, leaving 730 bp immediately downstream of the polyadenyl-
ation site. In this construct (PD1/Bam), the 1 Kb regulatory
region upstream of the TSS, the entire coding region and the poly
A addition site remained intact (Figure 1A, second panel). All eight
transgenic founder lines generated with this construct expressed
class I on the surface of peripheral blood lymphocytes (PBL)
(Figure 1A, second right panel). The overall pattern and level of
cell surface expression in B- and T-cells (Figure 1B, compare top
and bottom panels) and of RNA expression in tissues (Figure 1C;
Table 2; Figure S1) of the PD1/Bam mice paralleled that
previously reported for the original full-length 9 Kb MHC class I
transgene and endogenous MHC class I genes [22]. Furthermore,
PD1 transcription in PD1/Bam mice was activated by in vivo
interferon treatment (Weissman, unpublished observations). Thus,
all of the regulatory elements necessary for appropriate MHC class
I gene expression in vivo reside within the 5.3 Kb PD1/Bam DNA
segment.
To further map the necessary downstream elements and to
investigate their role(s) in regulating expression, we generated
transgenic mice from a series of constructs in which introns were
successively removed. A transgenic construct deleted of introns 3–6
(Figure 1A) (PD1cDNAint1-2/Bam) directed normal levels
(Figure 1A, third panel; Table 2) and patterns (Figure 1B, C;
Table 2; Figure S1) of expression in vivo. A transgenic construct
further deleted of all introns except intron 7 (PD1cDNA/Bam), was
also expressed in vivo (Figure 1D), as assessed by the presence of
transcripts in PBL and tissues. However, in contrast to the
PD1cDNAint1-2/Bam construct containing introns 1 and 2,
expression was barely detectable in PBL (Figure 1A, bottom panel)
and highly aberrant in other tissues relative to the genomic
transgene: Expression was disproportionately high in brain and low
in spleen, relative to liver, as assessed by RT-PCR or by northern
(Figure 1D).
Taken together, these data demonstrate that while PD1
promoter activity per se does not depend on the introns, introns
1 and/or 2 contain sequences necessary for normal tissue-specific
patterns of PD1 expression in vivo. Importantly, the reproducibility
of PD1cDNAint1-2/Bam expression and proper tissue distribution
among multiple independent transgenic lines indicates that this
short 4.0 Kb construct contains the minimal PD1 regulatory unit.
39 intergenic sequences are necessary for MHC class I
expression in vivo
The finding that in vivo expression of the PD1 gene does not
depend on introns 1–6 suggested that the required downstream
sequences are located within the 39 intergenic region, which is
present in all of the constructs that are expressed in vivo. To test this
possibility, we next asked whether the 39 terminus of the PD1/
Bam clone could restore expression to the silent PD1-CD2
transgene (Figure 1A). To this end, a 1.3 Kb BamHI fragment
encompassing the poly A addition site and 730 bp of 39 intergenic
sequences was inserted, in both orientations, downstream of the
CD2 coding sequence in the PD1-CD2 construct (PD1-CD2/
Bam(+) or PD1-CD2/Bam(2); Figure 2A, upper and lower panels,
respectively). In contrast to the parental PD1-CD2 construct, all of
the transgenic lines containing the PD1-CD2/Bam(+) construct
(5/5) and a majority (7/8) of those with the PD1-CD2/Bam(2)
expressed CD2, both on their PBL and in their tissues. (Figure 2A;
Table 1). Those with the 39 Bam segment in the forward
orientation generally expressed cell surface CD2 protein at higher
levels on PBL, despite their lower copy number (Figure 2A). Thus
sequences downstream of the PD1 coding region contain
regulatory elements necessary for expression.
Although the PD1-CD2/Bam(+) mice expressed surface CD2
on PBL, the patterns of expression of the CD2 transgene on
lymphocyte populations and in the tissues differed markedly from
the endogenous MHC class I and PD1 transgene patterns
(Figure 2B; data not shown). These results are consistent with
the observation that introns 1 and/or 2 of the PD1 gene are
necessary for proper tissue expression.
The 39 regulatory element(s) necessary for in vivo expression
could function either as enhancers that augment promoter activity
or as barrier elements that prevent silencing by encroachment of
heterochromatin. However, the 39 segment does not function as a
classical enhancer since the presence of the 1.3 Kb BamHI 39
segment in PD1-CD2/Bam(+) did not significantly augment class I
promoter activity relative to PD1-CD2 in transient transfections of
either murine L cells or human HeLa cells (Figure 2C).
These findings indicate the presence of a barrier element in the
39 intergenic segment of the PD1 gene.
Sequence elements 39 to the MHC class I gene have
barrier function
The minimal 39 sequences necessary for barrier activity were
determined by 39 truncation of PD1 cDNAint1-2/Bam intergenic
MHC Class I Barrier Element
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(Figure 3A). Most of the transgenic founders generated with this
construct (14/21) either failed to express in any tissue or displayed
a variegated pattern of expression on PBL (Figure 3B, C, left
panels). Only 7 of the founders displayed low level PD1 expression
on the surface of PBL and a normal pattern of RNA expression in
B and T cells and in the tissues (Figure 3B right panels, Figure 3C,
Table 2).
This variegation in the expression of the PD1cDNAint1-2/
PolyA construct among the independent founder lines contrasts
Figure 1. Sequences downstream of the MHC I promoter are required for proper surface expression on PBL in-vivo. (A) FACS profiles
(right panels) of PD1 or CD2 surface expression on PBL of mice carrying the transgenes with the 1 Kb PD1 promoter ligated to the huCD2 reporter
(PD1-CD2); full length PD1 (PD1/Bam) transgene or PD1 cDNA with the 39 Bam HI fragment (PD1cDNA/Bam), cDNA containing introns 1 and 2 with a
39 Bam HI fragment (PD1cDNAint1-2/Bam). (diagramed on left panels). PBL were stained with either anti-PD1 or anti-CD2 antibody, as described in
Materials and Methods. Transgene copy numbers are indicated in parenthesis. Red curves represent staining of negative control C57/BL6 mice with
the relevant antibody. Profiles are representative of all of the founders of each of the transgenic lines. (B) MHC class I expression patterns on B and T
cells. Surface expression of MHC class I on B and T cells derived from mice transgenic for PD1/Bam and PD1cDNAint1-2/Bam was assessed by dual
staining with anti-PD1 antibody and B220 (B cells) or Thy1.2 (T cells). The pattern of endogenous mouse MHC class I, K
b, expression on the PBL from
PD1/Bam mice was determined by staining with an anti- K
b antibody. The K
b and PD1 antibodies do not cross-react (data not shown). The results are
representative of multiple independent experiments. (C) PD1 RNA expression in PD1cDNAint1-2/Bam mice parallels that of PD1/Bam in different
tissues. PD1 RNA levels in tissues of transgenic mice were determined by both Northern analysis using a probe that spans exons 2–3 and that only
minimally cross-hybridizes with endogenous class I sequences. Relative levels of expression were quantitated by normalizing with an 18S RNA control
probe (graphs below northern). This experiment is representative of three independent experiments. qPCR analyses are shown in Figure S1. (D) PD1
expression in PD1cDNA/Bam transgenic mice is aberrant. RNA from PBL (right panel) or various tissues was probed with a class I probe, by Northern
as in (C) and normalized with GAPDH. The relative levels of expression in two individual PD1cDNA/Bam mice are shown in the left panel.
doi:10.1371/journal.pone.0006748.g001
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Bam, all eight of which expressed with normal tissue-specific
patterns. Therefore, sequences within the 39 intergenic region are
required for normal in vivo expression of PD1 and thus provide
barrier function.
Similar variegated expression was observed when the PD1
cDNAint1-2/PolyA, which does not retain barrier activity, was
extended by 79 bp to a downstream Sac site (PD1 cDNAint1-2/
Sac; Figure 3A, 4A). Of 10 founder lines generated from this
construct, only two showed levels of cell surface expression on PBL
comparable to the PD1cDNAint1-2/Bam mice, with a distribu-
tion between T and B cells that paralleled PD1cDNAint1-2/Bam
transgenic lines (Figure 4A, compare with Figure 1B). The
remaining lines either did not express PD1 (3/10) or had aberrant
expression patterns (5/10) on whole PBL, T cells and B cells
(Figure 4A).
Variegated patterns of RNA expression among the lines were
observed in the tissues as well, as determined by quantitative RT
real-time PCR of PD1 transcripts and Northern analysis
(Figure 4B, Table 2). Thus, restoration of only the 79 bp
immediately downstream of the PolyA addition site is insufficient
to overcome variegated expression. These results suggest that
stable transgene expression depends, at least in part, on regulatory
element(s) located in the 650 bp segment between the Sac I site
and the distal Bam H1 site (see Figure 3A).
39 intergenic sequences are necessary to maintain MHC
class I expression in stably transfected cell lines
To further characterize the barrier activity of the 39 intergenic
sequences, we turned to an ex vivo assay. Previous studies in
cultured cell lines have demonstrated that expression of stably
transfected genes lacking barrier elements is gradually extin-
guished in the absence of selective pressure, as heterochromatin
propagates into the transgene [30]. Therefore, we examined
whether 39 intergenic sequences are required to maintain PD1
expression in stably transfectedc e l l s ,a sf o l l o w s .S t a b l eLc e l l
transfectant clones of PD1cDNAint1-2/Bam, PD1cDNAint1-2/
Sac or PD1cDNAint1-2/PolyA constructs were isolated and
maintained in parallel without or with selective HAT medium.
Boundary function of the 39 intergenic region was assessed by
periodic monitoring of PD1 expression. Clones generated with
any of the three constructs all expressed comparable levels of cell
surface MHC class I when maintained in HAT selection
(Figure 5A). Clones transfected with PD1cDNAint1-2/Bam all
maintained expression for at least 4 months in the absence of
HAT (Figure 5A, left set of panels). In contrast, among clones
transfected with constructs deleted to either the PolyA site
(PD1cDNAint1-2/polyA) or to the SacI site (PD1cDNAint1-2/
Sac), the majority of the clones lost expression in the absence of
selection, as assessed both by surface expression and quantitative
real-time RT PCR (representative patterns are shown in Fig. 5A,
a n dF i g u r e5 B ;T a b l eS 2 ;t h et i m ec o u r s eo fl o s so fe x p r e s s i o no f
three of these clones is shown in Figure 5C). Thus, variegated
loss of expression among the stably transfected L cell clones
paralleled their expression pattern in transgenic mice, further
establishing the function of the 39 intergenic region as a barrier
element.
We used this ex vivo barrier assay to further define the barrier
element. Since the intergenic 79 bp segment between the polyA
site and the Sac I site alone did not restore barrier function
either in vivo or in L cell clones, we next asked whether the
presence of the distal intergenic segment between the Sac I site
and the Bam HI site alone was sufficient to restore barrier
function. To this end, the 79 bp polyA-SacI segment within the
stably expressed PD1cDNAint1-2/Bam was replaced by an
irrelevant pUC19 DNA sequence (PD1cDNAint1-2/Distal;
Table 1. MHC class I promoter driven expression of the CD2
transgene depends on the presence of intergenic sequences
39 to the class I gene.
Transgenic Line Brain Kidney Spleen Liver Thymus
PD1-CD2 0000 N D
PD1-CD2/Bam(+) 11.7 6.5 226.6 40.1 42.8
PD1-CD2/Bam(2) 1.0 13.6 206.6 12.1 55.3
RNA levels in each of the tissues were determined by qRT-PCR, normalized for
18S rRNA in the same sample.
ND – not determined. The results are the average of two independent
experiments.
doi:10.1371/journal.pone.0006748.t001
Table 2. Summary of PD1 transgene expression in different lines of PD1 transgenic mice.
Transgene
Normal Expression in
Iindependent Lines Line Expression by qRT-PCR
Animal Spleen Kidney Liver Brain Thymus
PD1/Bam 8/8 N/A N/A 12.7 2.3 2.9 1.6 10.9
PD1cDNAint1-2/Bam 8/8 418A4 #1 18.6 2.4 1.3 3.0 30.0
418A4 #2 29.5 0.12 1.5 0.41 1.0
418E4 #1 16.3 0.5 2.1 3.5 8.1
418E4 #2 22.0 1.6 1.3 1.8 1.8
PD1cDNAint1-2/Sac 2/10 564I7 (expresser) #1 10.7 1.0 1.2 2.5 9.5
564I7 (expresser) #2 20.5 1.5 0 3.3 14.0
564K6 (non-expresser on PBL) N/A 0 0 0 0 0
PD1cDNAint1-2/PolyA 7/21 730W6 (expresser) N/A 7 0.06 0.6 0.5 0.7
730N3 (non-expresser) N/A 0 0.1 0 0 0
C57BL/6 N/A N/A N/A 0 0 0 0 0
RNA levels in each of the tissues were determined by qRT-PCR, normalized for 18S rRNA in the same sample.
doi:10.1371/journal.pone.0006748.t002
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PLoS ONE | www.plosone.org 4 August 2008 | Volume 4 | Issue 8 | e6748Figure 2. 39 intergenic sequences are required for stable in-vivo expression of the MHC I gene, PD1. (A) FACS profiles of CD2 surface
expression on PBL of transgenic mice. Transgenic mice were generated with constructs containing the human CD2 reporter driven by the PD1
promoter (PD1/CD2) into which a segment 39 to PD1 coding sequences was inserted in either the forward (PD1-CD2/Bam(+)) or reverse orientation
(PD1-CD2/Bam(2)). The numbers in parentheses indicate the range of transgene copy numbers in different lines. (B) FACS profiles of huCD2
expression on B (B220) and T (Thy1.2) cells of PD1CD2/Bam(+) transgenic mice (pattern 1 from (A)). H-2K
b expression pattern in the same mice is
shown as control. (C) M12 cells were transiently transfected with PD1/CD2 or PD1-CD2/Bam(+). Surface expression was determined by FACS analysis
with anti-huCD2 antibody (left panels); relative surface expression (right panels) is the average level of expression and standard deviation among 3
independent transfections.
doi:10.1371/journal.pone.0006748.g002
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PLoS ONE | www.plosone.org 5 August 2008 | Volume 4 | Issue 8 | e6748Figure 3. Expression of a PD1 transgene is variegated in the absence of sequences 39 to the polyA site. (A) The positions of the polyA,
SacI and BamHI sites in the PD1cDNAint1-2/Bam construct are diagrammed and constructs generated from truncation at these sites indicated.
Numbers indicate the position relative to Hind III site at +1. (B)PD1 expression is variegated on PBL among transgenic lines carrying a PD1cDNAint1-2
construct truncated at the polyA site. PBL from the different PD1cDNAint1-2/polyA transgenic lines were stained with either anti-PD1 antibody alone
(left panels) or in combination with anti-B220 (B cells) (middle panels) or anti-Thy1 (T cells) (right panels). Shown are representative PD1 profileso f
each of the groups. The map of the construct is shown at the bottom. (C) RNA levels in different tissues of non-expresser and expresser PD1cDNAint1-
2/polyA transgenic lines were assessed by qPCR. Results shown from individual mice are representative of 2–3 individuals tested for each line. (The
small amounts of RNA detected in the thymus are not reproducibly observed.)
doi:10.1371/journal.pone.0006748.g003
MHC Class I Barrier Element
PLoS ONE | www.plosone.org 6 August 2008 | Volume 4 | Issue 8 | e6748Figure 4. Expression of a PD1 transgene is variegated in the absence of sequences 39 to the SacI site. (A) PD1 expression is variegated
on PBL among independent transgenic founder lines carrying a PD1cDNAint1-2 construct truncated at the SacI site. PBL from the different
PD1cDNAint1-2/Sac transgenic lines were stained with either anti-PD1 antibody alone (left panels) or in combination with anti-B220 (B cells) (middle
panels) or anti-Thy1 (T cells) (right panels). Shown are representative profiles of each of the groups. Numbers at the right show the number of
founder lines having the same pattern of expression. The map of the construct is shown at the bottom. (B) RNA levels among the different tissues of
non-expresser (left panels) and expresser (right panels) PD1cDNAint1-2/Sac transgenic lines were assessed by Northern using a probe that spans
exons 2–3 and only minimally cross-reacts with endogenous MHC class I (top panels); level of expression was quantitated relative to 18S RNA (middle
panels). RNA levels in various tissues of an independent set of mice were also measured in by qPCR and quantitated relative to 18S RNA (bottom
panels). Results shown from individual mice are representative of 2–3 individuals tested for each line.
doi:10.1371/journal.pone.0006748.g004
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this construct, seven lost expression to varying degrees in the
absence of selection (Figure 6 shows the time course of loss of
expression for four of the clones; Table S3). Thus, the distal
650 bp segment between the Sac and Bam sites is not sufficient
to maintain stable expression.
Since neither this segment nor the 79 bp interval between the
Poly A and Sac sites are able to provide complete barrier function
independently, both segments contribute to full barrier function.
If the 39 intergenic segment downstream of the polyA addition
site contains barrier function, as indicated by the above data, we
would predict that it would not be required for promoter activity
in the context of a minichromosome that is not integrated into
genomic DNA. Indeed, when cloned into the bovine papilloma
viral vector, p-REP7, and introduced into the human K562 cell
line (where it is maintained as an extrachromosomal episome
packaged into nucleosomes but not subject to heterochromatin
encroachment), the PD1cDNAint1-2/polyA construct is stably
expressed, both in the presence and absence of the selective
medium (data not shown).
Taken together, these studies functionally identified a complex
boundary element within the 39 downstream sequence of the
MHC class I gene between the poly A addition site and the distal
Bam site. Full boundary function depends on the presence of both
the 79 bp segment downstream of the polyA site and the DNA
segment between the Sac I site and the distal Bam H1 site (see
Figure 3A). Neither DNA segment alone is sufficient to confer
barrier activity; both are necessary. Whether barrier activity is
mediated by a continuous DNA element spanning the SacI site, or
by two discontinuous segments, remains to be determined.
Figure 5. Sequences 39 to the MHC I gene are required to maintain expression in stably transfected cells. (A) FACS profiles of three
representative stabletransfectantL cell clones(A,B,C)derivedfrom PD1cDNAint1-2/Bam, PD1cDNAint1-2/Sac and PD1cDNAint1-2/polyA maintainedw i t h
or without selection for 100 days and stained with anti-PD1 antibody. Gray curves represent the negative control. The numbers below the profiles are the
percentage of cells that have lost PD1 expression. Copy numbers in all lines varied between 2 and 6. (B) Relative PD1 RNA levels in PD1cDNAint1-2/Bam
and PD1cDNAint1-2/polyA clones A–C maintained with or without selection for 100 days, as determined by RT qPCR. Clones A–C correspond to the
respective clones in (A). (C) Kinetics of loss of PD1 surface expression of PD1cDNAint1-2/polyA lines after transfer to non-selective medium. Clones grown
in the presence and absence ofHATfor varioustimes wereassessed forsurface PD1 expression bystaining withanti-PD1 antibody and FACS analysis. The
relative level of surface expression is defined as the ratio of mean fluorescence units of the clones grown in the absence of HAT relative to the same clone
grown in the presence of HAT.
doi:10.1371/journal.pone.0006748.g005
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to maintain active MHC class I chromatin organization
and modifications
Barrier elements are required to maintain nucleosome organi-
zation and histone modifications associated with an open
chromatin structure [30]. Thus, the presence of barrier activity
in the 39 intergenic region downstream of the polyA site predicts
that both the nucleosome organization and histone modifications
of the class I gene will be affected by its absence. To determine
whether chromatin changes accompany gene silencing, we
assessed the effect of the barrier segment on the relative
nucleosome density across the gene in stable L cell transfectant
clones. In the selective medium, where expression is maintained
for all constructs, all three showed similar pattern of uniformly low
nucleosomal density (Figure S3). In the absence of selection,
nucleosomal density remained uniformly low across the PD1 gene
in PD1cDNAint1-2/Bam (which stably expressed PD1). In sharp
contrast, PD1cDNAint1-2/polyA clones that lost expression
acquired significantly increased nucleosomal density across the
gene (Figure 7A). Thus, nucleosomal density across the class I gene
correlates with expression status and with the presence of the full
730 bp intergenic segment containing 39 barrier function.
Surprisingly, loss of expression of the PD1cDNAint1-2/Sac
construct does not correlate with nucleosomal density, which was
almost uniformly low across the gene and indistinguishable from
the expressing PD1cDNAint1-2/Bam clone (Figure 7A). These
findings indicate that whereas the entire region extending from the
Poly A site to the distal Bam site is necessary for stable expression,
the activity located in the 79 bp between polyA and the Sac I site
is sufficient to maintain an ‘‘open’’ chromatin structure. Thus,
there are two separable barrier element activities.
To examine the relationship between barrier function and
histone modifications, we assessed chromatin modifications associ-
ated with active chromatin across the gene in the same clones that
were analyzed for nucleosomal density. Specifically, we assayed by
ChIP analysis for the presence of histone H3K9/K14 acetylation
and H3K4 dimethylation. As shown in Figures 7B and C, histone
H3K9/K14 acetylation and H3K4 dimethylation modifications
were reduced along the non-expressing PD1cDNAint1-2/polyA
construct compared to the PD1cDNAint1-2/Bam construct, in
agreement with the increase in nucleosomal abundance. Surpris-
ingly, but consistent with its low nucleosomal abundance, the non-
expressing PD1cDNAint1-2/Sac transfected clones displayed
histone modifications across the gene at levels comparable to the
fully-expressing PD1cDNAint1-2/Bam transgene clones. Thus, the
79 bp between the PolyA addition site and the Sac site contribute to
both barrier function and maintenance of histone modifications
associated with an active chromatin conformation. Importantly,
Figure 6. Loss of PD1 expression following deletion of 79 bases within the 39 intergenic region. Kinetics of loss of PD1 surface expression
from L cell lines stably transfected with PD1cDNAint1-2/distal after transfer to non-selective medium. Expression was monitored as described in
Figure 5. The PD1cDNAint1/2 construct from which 79 base pairs, between the polyA and SacI site were replaced with pUC19 sequences, to generate
PD1cDNAint1-2/distal is illustrated at the bottom.
doi:10.1371/journal.pone.0006748.g006
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PLoS ONE | www.plosone.org 9 August 2008 | Volume 4 | Issue 8 | e6748Figure 7. Altered chromatin organization is associated with deletions in the 39 intergenic region, independent of expression. (A)The
relative nucleosome density across the PD1 gene was determined as described in Materials and Methods in L cells stably transfected with
PD1cDNAint1-2/Bam, PD1cDNAint1-2/Sac and PD1cDNAint1-2/polyA and maintained in the absence of HAT medium. Although all three clones retain
the respective transgenes, only the PD1cDNAint1-2/Bam line expresses PD1. The results shown were derived with clones B in Figure 5A. The location
of primers used for determining nucleosomal occupancy are illustrated in the map below the graph. The abscissa corresponds to the sites amplified
as indicated on the map. (B) Relative levels of histone H3 K9/14 acetylation, and (C) histone H3K4 dimethylation. Materials and Methods, primers and
abscissa are the same as in (A). All results are representative of two to three ChIP of independent clones.
doi:10.1371/journal.pone.0006748.g007
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expression.
Interestingly, we did not observe increases in modifications
associated with stable heterochromatin, namely DNA CpG
methylation (Figure S2) or histone H3K9 di-methylation (data
not shown), on the promoter of the PD1cDNAint1-2/polyA.
CBP,PCAF and H2A variant H2A.Z are associated with the
MHC class I gene barrier region
Histone modifying enzymes have been reported to be associated
with barrier elements, thereby actively regulating chromatin
modifications [31]. In light of the differences in chromatin
organization and modifications among the constructs, we assayed
by ChIP for the presence of the histone acetyl transferase enzymes,
CBP and PCAF across the PD1cDNAint1-2/Bam gene in L cells.
Indeed, we found that both CBP and PCAF were associated with
the 39 intergenic region as well as with the promoter (Figure 8A).
Among the transcription factors that have been identified within
boundary complexes are Upstream Factors 1 and 2 (USF1 and
USF2), which recruit histone modifying enzymes to the beta-
globin barrier element [31,32] and occupy the alpha-spectrin
barrier element as well [33]. Although both factors were found at
upstream sites, associated with the extended promoter (Figure 8A;
[34]), neither factor was detected in the class I 39 boundary region,
despite the presence of multiple E box sequences within the 39
intergenic region (Figure 8A; Table S1). These results indicate that
a different mechanism is employed for the recruitment of the
above enzymes to the MHC class I barrier element than has been
reported for the chicken beta globin boundary element.
The enhancer-blocking factor, CTCF, interacts with both b-
globin [35] and MHC class II [36] boundary elements which
contain both barrier and enhancer blocking functions. However,
we found no evidence in PD1cDNAint1-2/Bam in L cells that
CTCF interacts with the MHC class I barrier element (Figure 8A).
In contrast, CTCF was clearly detected within 600 bp of the PD1
promoter (Figure 8A).
The presence of histone variant H2A.Z in chromatin has been
associated with barrier function [37–39] and with promoters [40–
42]. Indeed, H2A.Z was associated both with sequences in the 39
barrier region of PD1cDNAint1-2/Bam and at higher levels at the
59 promoter region (Figure 8B)
In summary, the above studies have demonstrated the presence
of a complex barrier activity within the 39 intergenic region of the
MHC class I, PD1, gene that is required for stable expression of
the gene and for maintaining an open chromatin structure.
Discussion
The MHC class I genes, whose products play a critical role in
immune homeostasis, are primarily regulated transcriptionally.
Past studies on understanding the relationship between transcrip-
tional regulation and immune function have largely focused on
characterizing the regulatory elements and transcription factors
that govern their transcription. The core promoter and 59
extended promoter region of the MHC class I gene, PD1, contain
elements that mediate regulation of both constitutive, tissue-
specific levels of MHC class I expression and of immune activated
expression [2,3,5,6,24,25]. We now have extended the identifica-
tion and characterization of critical transcriptional regulatory
elements to sequences downstream of the promoter. We find that
normal expression of the MHC class I gene, PD1, in vivo depends
on both intronic and 39 intergenic sequences. Element(s) within the
introns are necessary for normal, tissue-specific levels of expres-
sion. A novel barrier element located in the 39 intergenic region is
necessary for sustained in vivo PD1 promoter activity and thus is an
important component of MHC class I immune function.
Although transcribed at very different levels in different tissues,
the PD1 promoter is constitutively in an open chromatin
conformation regardless of transcriptional activity, enabling the
cells to respond rapidly to infection by intracellular pathogens by
increasing MHC class I transcription rates without chromatin
remodeling [28]. In the current study, we show that this open
chromatin conformation depends on the presence of the 39
intergenic barrier element, which blocks heterochromatin en-
croachment and silencing. Removal of the barrier element results
in loss of expression accompanied by increased nucleosomal
occupancy and reduced active chromatin modifications across the
gene. Thus, the barrier element has two functions: (1) maintaining
stable expression, and (2) maintaining active chromatin modifica-
tions. Importantly, these two functions are distinct and physically
separable: partial truncation of the barrier element results in loss of
expression without a concomitant loss of the active chromatin
modifications. These findings lead to the conclusion that an active
chromatin structure is not sufficient to support gene expression,
absent other elements within the barrier.
The separation of chromatin modifying activities and sustained
expression found in the mammalian MHC class I, PD1, barrier
element is similar to that observed in the chicken b-globin 59
compound boundary element that separates the gene locus from
an upstream 16 Kb heterochromatin domain [31]. This boundary
element consists of five protein binding sites, all of which are
necessary for its function. Recruitment of histone modifying
enzymes to one of these sites terminates heterochromatin
spreading by generating an active chromatin conformation at
the barrier. Similar to the PD1 barrier, recruitment of histone
modifying enzymes and the resulting histone modifications at the
b-globin promoter and gene are necessary but not sufficient for the
barrier activity [31]. We speculate that in both cases genomic
barriers require the combined function of distinct complexes with
different activities.
Although alone it is not sufficient to sustain transcription, active
chromatin structure contributes to MHC class I barrier function.
The binding of CBP and PCAF to the 39 intergenic region of PD1
suggests that the mechanism of the MHC class I barrier function
involves active recruitment of histone modifying enzymes. Indeed,
histone modifying enzymes have been implicated in mediating the
activities of barriers associated with other genes [31,32,43,44]. We
speculate that CBP and PCAF may be involved in the anti-
silencing function of the MHC class I barrier element. The precise
sequences that are involved in recruitment of histone modifying
enzymes are yet to be determined. It is possible that they are
within or flanking the 79 bp sequence downstream of the
polyadenylation signal, deletion of which resulted in altered
chromatin arrangement and loss of expression.
Since neither CBP nor PCAF bind DNA directly, they must be
recruited to the barrier element by one or more transcription
factors. USF1/2 has been shown to play a critical role in mediating
barrier activity of the chicken b globin gene, recruiting histone
modifying enzymes [31,32]. USF1/2 is also associated with a
barrier element located within the alpha-spectrin gene [33].
However, no binding of USF1 or USF2 to the PD1 39 intergenic
region was detected, either in vivo or in in vitro gel shift assays (data
not shown), despite the presence of a consensus E box binding sites
within the 39 intergenic barrier region. The transcription factor(s)
that recruits CBP and PCAF to the PD1 barrier remains to be
identified. In initial gel shift studies with HeLa nuclear extract, a
complex dependent on sequences within the 79 bp segment
between the polyA addition site and the Sac I site was observed
MHC Class I Barrier Element
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any known canonical binding sites and it was not possible to identify
the cognate factors. The HMG box containing protein, HBP1, has
been shown to bind to an element with barrier function within the
locus control region of the human CD2 gene [45]. Although a half-
site occurs with the PD1 39 intergenic sequence, the full HBP1
binding site, TTCATTCATTCA, does not. Moreover, DNA
sequence homology searches did not identify any additional known
binding sites within the entire 39 intergenic region.
The histone variant, H2A.Z, interacts with both promoters and
barrier elements in yeast [37–39] and vertebrates [40,41],
suggesting that it also may contribute to barrier function. The
association of H2A.Z with the intergenic region suggests it may
take part in the barrier function of the PD1 gene as well.
Figure 8. Histone modifying enzymes and histone variant H2A.Z are associated with PD1 39 intergenic sequences. (A) ChIP analysis
was performed on L cells stably transfected with PD1cDNAint1-2/Bam, as described in Materials and Methods, to determine the extent of association
of CTCF, CPB, PCAF, USF1 and USF2 across the PD1 gene, as indicated. All three 39 UTR primers gave the same results; only 39UTR(1) is shown. (B) The
binding of histone variant H2A.Z across the PD1 gene was similarly determined in the same clone. All results shown are representative of two ChIP
experiments of independent clones. None of the 39UTR primers showed any amplification following ChIP with anti-H2A.Z.
doi:10.1371/journal.pone.0006748.g008
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acquisition of repressive chromatin marks. Modifications associat-
ed with silenced genes, H3K9 dimethylation and promoter CpG
methylation, did not appear in the absence of the barrier element.
Consistent with these findings, several studies have shown that
transcriptional silencing by heterochromatin propagation is a
gradual process, composed of stepwise formation of heterochro-
matin, leading to the existence of intermediate state heterochro-
matin, in which silencing is partial and histone modifications are a
mixture of active and inactive chromatin [46–48] while DNA
CpG methylation appears long after the gene is silenced [48]. The
latter modification appears to be involved in maintenance, rather
than establishment, of transcriptional silencing [48,49]. In
accordance with these observations, lack of H3K9 dimethylation
and DNA methylation of the PD1 transgene truncated at the
barrier site is consistent with intermediate transcriptional silencing
and suggest the existence of yet other elements that contribute to
boundary activity.
In conclusion, the PD1 barrier element, like other functionally
defined barrier elements, serves to sustain gene expression and to
maintain histone modifications and low nucleosomal density
associated with active transcription [30–32,38,44,48,50–63]. In
the complete absence of the intergenic barrier element, expression
is extinguished with the accompanying loss of histone modifica-
tions and increased nucleosomal density. Surprisingly these
modifications are not sufficient to retain expression. Loss of both
expression and chromatin modification requires truncation of the
entire intergenic segment. The striking conclusion from these
findings is that active chromatin modifications and structure are
not sufficient to maintain expression of the MHC class I, PD1,
gene. Future experiments will further define the function of the
MHC class I barrier element.
Materials and Methods
DNA Constructs
PD1/Bam extends from the Hind III site approximately 1 Kb
59 of the PD1 promoter through the entire coding sequence
(CDS),and 730 bp beyond the poly A addition sites to a Bam HI
site in the 39 intergenic region cloned in pBR322 (Figure 1A).
PD1cDNAint1-2/Bam was generated from PD1/Bam by replac-
ing a BbvcI/BamHI genomic fragment, spanning exon 3 through
exon 7 with a BbvcI/BamHI cDNA fragment that contained only
the exons (Figure 1A). PD1cDNAint1-2/Sac was generated by
truncation of the PD1cDNAint1-2/Bam to the 39 Sac I site 79 bp
beyond the poly adenylation signal (Figure 3A). PD1cDNAint1-2/
polyA was generated by cloning of the PD1 cDNA sequence into
the Sal I site of pUC19 and replacing the 59 segment containing
the first two exons with a genomic HindIII/NcoI sequence
including the 1 Kb upstream regulatory region through exon 3
thereby including the first 2 introns (figure 3A). To construct the
PD1cDNAint1-2/distal clone, a DNA segment extending from the
distal 39 Sac I site to the distal BamHI site was inserted
downstream of PD1cDNAint1-2/polyA (Figure 3A), into the
BamHI site of the pUC19 vector, thereby replacing 79 bp PD1
with pUC19 sequences. The PD1/CD2 construct was generated
by cloning a 1.1 Kb fragment containing the PD1 promoter
upstream of the hCD2D74 cDNA construct (gift of D. Littman,
NYU) (Figure 1A). PD1/CD2-39(+) and PD1/CD2-39(2) were
generated from PD1/CD2 by inserting a genomic 1.3 Kb BamHI
fragment of PD1, spanning intron 7, exon 8, the 39UTR and 39
intergenic sequences into the Sal/BstI site immediately 39 of the
CD2 gene (Figure 2A).
Transgenic mice
Transgenic mice were generated as described previously [22],
and screened by either Southern blotting or PCR of genomic tail
DNA. All animal work was approved by the NIH Animal Care
and Use Committee. Animals were housed and handled in strict
accordance with ALAC requirements under the NIH protocol
EIB-086.
Transfections
For transient transfection assays, 1610
6 HeLa cells were
transfected with 10 mg of DNA using Lipofectamine (Gibco/
Invitrogen, Grand Island, NY) according to manufacturer’s
protocol. M12 cells were transfected as described before [3].
For stably transfected Ltk(2) clones, 1610
6 cells were co-
transfected with 0.5 mg of the indicated clone DNA and 10 mg
plasmid containing the thymidine kinase gene (TK) using
Lipofectamine. The cells were maintained in DMEM for 48 hours
and then the medium was replaced with fresh DMEM containing
1% hypoxanthine-aminopterine-thymidine (HAT). Isolated clones
were analyzed for PD1 expression by FACS.
Flow cytometry
FACS was carried out as described before [64], using antibodies
detailed below; except for PD1 surface expression, in which case
cells were stained with unlabeled primary Ab followed by goat
anti-mouse secondary Ab conjugated to FITC (SouthernBiotech,
Birmingham, AL). FACS results were analyzed using FlowJo.
Antibodies: PD1 surface expression in mouse peripheral blood
lymphocytes (PBL) and mouse cell lines was analyzed using PT85
anti-SLA antibody (VMRD Inc, Pullman, WA) while human cell
lines were screened using the anti-SLA antibody 74-11-10
(VMRD). Other antibodies used for FACS analyses were: human
CD2 (Pharmingen), B220 (BD-Pharmingen), Thy1.2 (BD-Phar-
mingen), H-2 Kb (BD-Pharmingen).
Northern blot analysis and real-time RT-PCR
RNA was prepared using Trizol (Invitrogen). Northern blotting
and real-time RT-PCR for PD1 analyses were done as described
before [28]. For CD2 blots, full-length human CD2 cDNA
fragment was used to probe for CD2 RNA.
Nucleosome density
Nuclei were prepared from 1610
8 Ltk(2) cells stably co-
transfected with TK plasmid and different PD1 constructs
according to the protocol published by O’Neill and Turner [65].
DNA was purified using phenol-chloroform extraction followed by
ethanol precipitation and subjected qPCR; amplification across
the gene for all cell lines was corrected for copy number and
normalized to the amplification from PD1cDNAint1-2/Sac clone
using the -100 primer set.
Chromatin Immunoprecipitation
Native chromatin immunoprecipitation (N-ChIP) was per-
formed to analyze histones modifications according to the protocol
published by O’Neill and Turner [65] with the addition of
preclearing step prior to immunoprecipitation with 75 mlo f
salmon sperm DNA/protein A agarose beads (Upstate, NY) for
one hour at 4uC. Antibodies that were used for detecting histones
modifications are: anti dimethyl Histone H3 Lys4 (Upstate, 07-
030), anti acetyl Histone H3 Lys 9/14 (Upstate, 06-599), anti
dimethyl Histone H3 Lys9 (upstate, 07-441), anti Histone H2A.Z
(Abcam, ab-4174). A no antibody control was included as well.
Cross-linked ChIP (X-ChIP) was used to test for binding factor
according to protocol published by Upstate and using Upstate
MHC Class I Barrier Element
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1610
6 Ltk(2) cells stably transfected with PD1cDNAint1-2/5-1
construct were crosslinked as detailed in the published protocol,
followed by addition of 0.125 M glycine for five minutes at room
temperature to stop the crosslinking reaction. Cells were washed
twice with ice-cold PBS in the presence of protease inhibitors and
then resuspended in SDS lysis buffer. The cells lysates were then
sonicated in the presence of glass beads to give fragments size
ranging from 1–0.3 Kb. ChIP proceeded according to the
published protocol, using the following antibodies: anti CTCF
(Santa cruz, sc15914x), anti USF1 (santa cruz, sc-229x), anti USF2
(Santa cruz, sc-861x), and anti CBP (santa cruz, sc-369), followed
by reversal of crosslinking by over night incubation with NaCl at
65uC. A no antibody control was included as well.
Quantitation of ChIP results
DNA immunoprecipitated by N-ChIP or X-ChIP reactions was
analyzed by real time PCR using the following primers:
Promoter primers:
(-1000): sense: 59 TACATATGAAACACTCCTGCTACCT-
TCC; antisense: 59 CCAGTAAAGGTTGTATTCCATGA
(-600): sense: 59 TGTGCGGGGCT TTTACATTTC; anti-
sense: 59 CACTGGAGGTTTATGTCTGCTTCTG
(-100): sense: 59 CGCAACCTGTGTGGGAC; antisense: 59
GGGTGGGTGGAGAGTTT
Coding region:
intron 1: sense: 59 GAACAAGGCCGCTGCG; antisense: 59
CAGCAGA GTCGCACCTTC
Exon 5; sense: 59 CAGACCCTGCTCAGCCC 39; antisense: 59
G GGTGGGTGGAGAGTTT
39 end:
39UTR(1): sense: 59 TCTGTGTTCCTATGAGCATCC; an-
tisense: 59GAACAC AGGTCAGGGTGAG
39UTR(2): sense: 59CTGACATCTCCATCCTTACT; anti-
sense: 59 CCTCATGGCACCAATTAGAA
39UTR(3): sense: 59 TGCCATGAGGAGTTGAGG GGA-
TAATAAA; antisense: 59 GGATTCTGGAAGGTTCTCA
39distal(1): sense: 59 ATTCAGGAGCTTGGTTAGCAA; an-
tisense: 59 GCCAAATACA AACACAGAATAAA
39distal(2): sense: 59 CCTCCTTCCAGAGATGTTTA; anti-
sense: 59 ACCTCCATGTGCCGTGAGT
39distal(3): sense: 59 GGGTCTAATCAGAGCTACAG; anti-
sense: 59 AGCATTGCTGTGTGTTGTGG
Quantitative real-time PCR was performed using ABI7900 with
SYBR green real time PCR kit (Applied Biosystems). Results were
calculated as percentage bound/input DNA as compared to no
antibody control.
CpG methylation
GenomicDNAwasprepared fromLtk(2) clones stably transfected
with PD1cDNAint1-2/Bam, PD1/Sac and PD1/polyA. The DNA
was digested with HpaII (CpG methylation sensitive) or Msp I (CpG
methylation insensitive). After digestion, the DNA was precipitated
and a promoter region spanning two HpaII/Msp I restriction sites
was amplified in a real time qPCR reaction using (2100) primers (see
above). Results were calculated as percentage PCR product of non-
digested DNA amplified with the same primers.
Supporting Information
Figure S1 Tissue expression pattern of PD1cDNAint1-2/Bam
transgenic mice parallels that of PD1/Bam transgenic mice. RNA
was isolated from the indicated tissues and assessed by qPCR for
the levels of PD1 specific RNA using a primer that spans exons 2–
3. RNA levels were quantitated relative to an 18S rRNA internal
control.
Found at: doi:10.1371/journal.pone.0006748.s001 (0.01 MB
PDF)
Figure S2 Loss of PD1 expression in the absence of 39 intergenic
sequences is not associated with promoter CpG methylation. DNA
was isolated from L cell clones stably transfected with
PD1cDNAint1-2/Bam, PD1cDNAint1-2/Sac and PD1cDNAint1-
2/polyA and maintained in the absence of HAT medium. Although
all three clones retain the respective transgenes, only the
PD1cDNAint1-2/Bam line expresses PD1. CpG methylation at
the promoter in each of the clones was determined as described in
Supplementary Experimental Procedures. Results show real time
PCR amplification of PD1 promoter region after digestion with Hpa
II or Msp I, relativeto non-digested DNA. Results are representative
of three independent clones from each construct.
Found at: doi:10.1371/journal.pone.0006748.s002 (0.06 MB TIF)
Figure S3 39 intergenic sequences do not affect nucleosomal
organization of expressed PD1 genes in the presence of selective
pressure. Nucleosomal occupancy was determined across the PD1
gene in L cell clones stably transfected with PD1cDNAint1-2/
Bam, PD1cDNAint1-2/Sac and PD1cDNAint1-2/polyA and
maintained in the presence of HAT medium. All three clones
expressed the PD1 gene to comparable levels.
Found at: doi:10.1371/journal.pone.0006748.s003 (1.27 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0006748.s004 (0.03 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0006748.s005 (0.03 MB
DOC)
Table S3
Found at: doi:10.1371/journal.pone.0006748.s006 (0.03 MB
DOC)
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